托伐普坦辅助治疗对急性心力衰竭患者的HR、SBP、 BNP 及24 h尿量的影响

何丽，徐利莎

（中铁一局西安医院心内科，陕西 西安，710050）

浏览次数：115次 下载次数：361次

摘要：

目的 研究托伐普坦辅助治疗对急性心力衰竭患者的临床疗效。方法 选取我院2016 年2 月至2017 年2 月收治的急性 心力衰竭患者94 例为研究对象，采用随机数字法将其分为对照组和观察组，每组47 例。对照组患者接受常规抗心衰治疗， 在此基础上，观察组患者口服托伐普坦治疗。比较两组患者的临床疗效。结果 观察组患者的治疗总有效率为91.49%，高于对 照组的63.83%（P<0.05）。治疗后，两组患者的HR、SBP 及血清BNP 水平降低、24 h 尿量增多，且观察组的上述指标均优于对 照组（P<0.05）。治疗后，两组患者的LVEF 和SV 明显升高，且观察组高于对照组（P<0.05）。结论 托伐普坦辅助治疗对急性心 力衰竭患者的临床疗效显著，可明显改善心脏功能，提高心肌收缩能力，且治疗安全性高，值得在临床推广。

关键词：托伐普坦；急性心力衰竭；心功能

中图分类号：R541.6文献标志码：A文章编号：2096-1413(2018)02-0019-03

Effect of tolvaptan adjuvant therapy on HR, SBP, BNP and 24 hour urine volume in patients with acute heart failure
HE Li, XU Li-sha
(Cardiology Department, Xi``an Hospital of China Railway First Bureau, Xi``an 710050, China)

ABSTRACT: Objective To study the clinical curative effect of tolvaptan adjuvant treatment in patients with acute heart failure. Methods A total of 94 patients with acute heart failure in our hospital from February 2016 to February 2017 were selected, and randomly divided into control group and observation group, with 47 cases in each group. The control group received conventional anti heart failure treatment, on this basis, the observation group accepted tolvaptan oral treatment. The curative effects were compared in the two groups. Results The total effective rate of the observation group was 91.49%, which was higher than 63.83% of the control group (P<0.05). After treatment, the levels of HR, SBP and serum BNP in both groups decreased and urine volume increased, and the above indexes in the observation group were better than the control group (P <0.05). After treatment, the LVEF and SV significantly increased in both groups, and those of the observation group were higher than the control group (P<0.05). Conclusion Tolvaptan adjuvant therapy has the significant effect on acute heart failure, which can obviously improve heart function and myocardial contractility, with high safety, it is worthy of clinical promotion.
KEYWORDS: tolvaptan; acute heart failure; heart function

参考文献：
[1] 晏彪,陈振云,俞飞虎,等.左西孟旦联合托伐普坦治疗急性心力衰竭的疗效观察[J].心脑血管病防治,2016,16(6):465-466,468.
[2] SUZUKI S,YOSHIHISA A,YAMAKI T,et al.Long -term effects and prognosis in acute heart failure treated with tolvaptan: the AVCMA trial[J].BRI,2014,14(20):704-711.
[3] 王喜福,杨赓,曾玉杰.托伐普坦治疗老年顽固性心力衰竭伴低钠 血症患者的临床效果观察[J].中国医药,2015,10(6):790-792.
[4] 王晓琳,周元丽,孙伟,等.托伐普坦联合左西孟旦治疗顽固性心力 衰竭的疗效观察[J].中国药房,2016,17(8):1074-1077.
[5] 刘斌.新活素、左西孟旦和托伐普坦联合应用治疗顽固性心力衰 竭疗效观察[J].国际心血管病杂志,2015,42(6):431-432.
[6] CASTRINI AI,CARUBELLI V,LAZZARINI V,et al.Serelaxin a novel treatment for acute heart failure[J].Expert Rev Clin Pharmacol,2015,8 (5):549-557.
[7] 陈鑫,王上,高玲,等.托伐普坦对急性心衰患者的疗效评价[J].中国 心血管病研究,2015,13(7):621-624.
[8] FELKER GM,MENTZ RJ,COLE R,et al.Efficacy and safety of tolvap原 tan in patients hospitalized with acute heart failure[J].J Am Coll Cardiol,2016,69(11):1399-1406.
[9] 王伟,边瓯,马宁,等.小剂量托伐普坦联合呋塞米治疗急性心力衰竭合并利尿剂抵抗超高龄老年患者临床评价[J].临床军医杂志,2016,44(6):601-604.
[10] 彭丹丹.托伐普坦治疗难治性心力衰竭患者效果的观察[J].岭南心血管病杂志,2016,22(2):181-183.